Cidofovir for recurrent respiratory papillomatosis (RRP): a re-assessment of risks.
Derkay
C
C
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D002273:Carcinogens / Q000008:administration & dosage*; D002648:Child; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017277:Drug Approval; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000821:virology; D063065:Organophosphonates / Q000627:therapeutic use*; D030361:Papillomavirus Infections / Q000188:drug therapy*; D012142:Respiratory Tract Neoplasms / Q000188:drug therapy* / Q000821:virology; D018570:Risk Assessment; D012720:Severity of Illness Index; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D002273:Carcinogens; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir